$KPTI

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Forbearance Agreement On September 10, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures (the “Forbearance Agreement”) to pr

Karyopharm Therapeutics (KPTI) granted 1,850 RSUs to two new employees under Nasdaq Rule 5635(c)(4). The RSUs vest over three years, contingent on continued service. Karyopharm focuses on cancer therapies, with XPOVIO as its lead treatment for multiple myeloma.

Karyopharm (KPTI) submitted an sNDA to the FDA for accelerated approval of XPOVIO combined with ruxolitinib to treat myelofibrosis, based on Phase 3 SENTRY trial data. The FDA previously granted Orphan and Fast Track designations to the therapy. KPTI stock is up 3.04% in pre-market trading.

Karyopharm Therapeutics (KPTI) reported Q2 earnings, highlighting a potential FDA accelerated approval for its myelofibrosis combination therapy, while also facing a cash crunch with funds lasting only until September. The company's selinexor and ruxolitinib combination showed promising results, but a $15.8 million loan payment due soon could trigger a default if not addressed. Karyopharm is exploring financing options and strategic alternatives.

Karyopharm (KPTI) reported Q2 2026 revenue of $33.4M, down from $37.9M YoY due to expired agreements. U.S. XPOVIO revenue rose to $30.8M. Net loss was $67M, including non-cash expenses. The company faces a $15.8M debt payment in September, risking a liquidity covenant breach. Management reaffirmed full-year revenue guidance of $130M-$150M and plans to submit an sNDA for selinexor in myelofibrosis.

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.

Karyopharm (Nasdaq: KPTI) reported Q2 2026 revenue of $33.4M, including U.S. XPOVIO (selinexor) net product revenue of $30.8M. The company said an sNDA for selinexor plus ruxolitinib in myelofibrosis is planned for August under the Accelerated Approval pathway. It reaffirmed 2026 revenue guidance of $130M to $150M.

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Rema

Karyopharm Therapeutics Inc. (KPTI) shares fell about 68% after the company reported topline results from its Phase 3 XPORT-EC-042 trial. The trial did not meet its primary endpoint of progression-free survival. The stock dropped 68.17% to $2.2350 on Nasdaq from $7.01 prior close.

Karyopharm Therapeutics (KPTI) reported topline results from its Phase 3 XPORT-EC-042 trial of selinexor as maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer. The trial missed the primary endpoint for progression-free survival, though median PFS was 12.75 months vs 7.43 months with placebo in 236 patients. No new safety signals were reported; full data planned for a medical meeting.